ArticleFuture oncology (London, England)2025
Real-world treatment outcomes of abemaciclib in older patients with HR+, HER2- metastatic breast cancer in Japan.
Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sacituzumab govitecan in Japanese participants with HR+/HER2- metastatic breast cancer: primary results from the phase II ASCENT-J02 study.Japanese journal of clinical oncology · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo understand the real-world use of abemaciclib in older patients (≥65 years) with HR+, HER2- metastatic breast cancer (MBC) in Japan.
methodsThis study retrospectively analyzed a Japanese administrative claims database for patients with HR+, HER2- MBC who received abemaciclib as the first CDK4/6 inhibitor (CDK4/6i) from November 2018 to May 2023. Patient characteristics and treatment patterns were summarized. Median time to discontinuation (mTTD) and chemotherapy-free survival (CSF) was estimated using Kaplan - Meier method.
resultsAmong 3,699 abemaciclib-treated patients with HR+, HER2- MBC, 1,681 (45.4%) were ≥65 years old. Among these, abemaciclib + fulvestrant (55.0%) was the most common regimen. The mTTD (95% CI) of first abemaciclib therapy was 12.8 months (11.4-13.6). The overall mTTD (95% CI) with all the BC drugs after starting abemaciclib was 40.2 months (37.0-44.0). The median (95% CI) CFS after starting abemaciclib was 34.8 months (30.2-39.5). Among 1,149 older patients who discontinued the abemaciclib therapy, 897 (78.1%) patients received subsequent treatment. The most common first subsequent therapy was the endocrine therapy + CDK4/6i regimen (34.9%).
conclusionThis study indicated that abemaciclib regimens were feasible for older patients with HR+, HER2- MBC in Japan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.